In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus

Overview

Journal Yonsei Med J

Specialty General Medicine

Date 2016 May 19

PMID 27189271

Citations 6

Authors

Joo Young Kim

Jun Chang

Affiliations

Soon will be listed here.

Abstract

Human respiratory syncytial virus (RSV) is the leading cause of severe lower respiratory tract infection, such as bronchiolitis, bronchitis, or pneumonia, in both infants and the elderly. Despite the global burden of diseases attributable to RSV infection, no clinically approved vaccine is available, and a humanized monoclonal antibody for prophylaxis is not readily affordable in developing countries. There are several hurdles to the successful development of RSV vaccines: immune-vulnerable target populations such as premature infants, pregnant women, and immunocompromised people; safety concerns associated with vaccine-enhanced diseases; repeated infection; and waning memory. To develop successful strategies for the prevention of RSV infection, it is necessary to understand the protective and pathologic roles of host immune responses to RSV infection. In this review, we will summarize the positive and negative relationship between RSV infection and host immunity and discuss strategies for the development of the first successful RSV vaccine.

Citing Articles

Activated Leukocyte Cell Adhesion Molecule Regulates the Expression of Interleukin-33 in RSV Induced Airway Inflammation by Regulating MAPK Signaling Pathways.

Baek S, Kim M, Kim E, Lee Y, Park C, Kim M Lung. 2024; 202(2):127-137.

PMID: 38502305 DOI: 10.1007/s00408-024-00682-6.

MiR-146a alleviates lung injury caused by RSV infection in young rats by targeting TRAF-6 and regulating JNK/ERKMAPK signaling pathways.

Huang Z, Liu X, Wu X, Chen M, Yu W Sci Rep. 2022; 12(1):3481.

PMID: 35241728 PMC: 8894416. DOI: 10.1038/s41598-022-07346-6.

Autophagic protein ATG5 controls antiviral immunity via glycolytic reprogramming of dendritic cells against respiratory syncytial virus infection.

Oh D, Park J, Jung H, Kim H, Lee H Autophagy. 2020; 17(9):2111-2127.

PMID: 32816604 PMC: 8496528. DOI: 10.1080/15548627.2020.1812218.

Chitinase 3-like 1 protein plays a critical role in respiratory syncytial virus-induced airway inflammation.

Kim M, Shim D, Cha H, Moon K, Yang C, Hwang S Allergy. 2018; 74(4):685-697.

PMID: 30402955 PMC: 7159489. DOI: 10.1111/all.13661.

Human respiratory syncytial virus and hospitalization in young children in Italy.

Kuhdari P, Brosio F, Malaventura C, Stefanati A, Orsi A, Icardi G Ital J Pediatr. 2018; 44(1):50.

PMID: 29728106 PMC: 5935991. DOI: 10.1186/s13052-018-0492-y.

References

Lopez J, Bustos R, Orvell C, Berois M, Arbiza J, Melero J . Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol. 1998; 72(8):6922-8. PMC: 109907. DOI: 10.1128/JVI.72.8.6922-6928.1998. View

Feldman S, Hendry R, Beeler J . Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. J Virol. 1999; 73(8):6610-7. PMC: 112745. DOI: 10.1128/JVI.73.8.6610-6617.1999. View

Kim H, Canchola J, BRANDT C, Pyles G, Chanock R, Jensen K . Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969; 89(4):422-34. DOI: 10.1093/oxfordjournals.aje.a120955. View

Hall C, Powell K, MacDonald N, Gala C, Menegus M, Suffin S . Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986; 315(2):77-81. DOI: 10.1056/NEJM198607103150201. View

Falsey A, Singh H, Walsh E . Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol. 2006; 78(11):1493-7. DOI: 10.1002/jmv.20724. View

Rudd B, Smit J, Flavell R, Alexopoulou L, Schaller M, Gruber A . Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J Immunol. 2006; 176(3):1937-42. DOI: 10.4049/jimmunol.176.3.1937. View

Openshaw P, Chiu C . Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol. 2013; 3(4):468-74. PMC: 4295022. DOI: 10.1016/j.coviro.2013.05.005. View

Fulton R, Meyerholz D, Varga S . Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol. 2010; 185(4):2382-92. PMC: 2923480. DOI: 10.4049/jimmunol.1000423. View

Graham B, Bunton L, Wright P, Karzon D . Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest. 1991; 88(3):1026-33. PMC: 295511. DOI: 10.1172/JCI115362. View

10.

Malloy A, Falsey A, Ruckwardt T . Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol. 2013; 372:211-31. DOI: 10.1007/978-3-642-38919-1_11. View

11.

Garofalo R, Patti J, Hintz K, Hill V, Ogra P, Welliver R . Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis. 2001; 184(4):393-9. DOI: 10.1086/322788. View

12.

Calder L, Gonzalez-Reyes L, Wharton S, Skehel J, Wiley D, Melero J . Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology. 2000; 271(1):122-31. DOI: 10.1006/viro.2000.0279. View

13.

Gomez M, Mufson M, Dubovsky F, Knightly C, Zeng W, Losonsky G . Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J. 2009; 28(7):655-8. DOI: 10.1097/INF.0b013e318199c3b1. View

14.

Lukacs N, Smit J, Mukherjee S, Morris S, Nunez G, Lindell D . Respiratory virus-induced TLR7 activation controls IL-17-associated increased mucus via IL-23 regulation. J Immunol. 2010; 185(4):2231-9. PMC: 3006454. DOI: 10.4049/jimmunol.1000733. View

15.

Wythe S, Dodd J, Openshaw P, Schwarze J . OX40 ligand and programmed cell death 1 ligand 2 expression on inflammatory dendritic cells regulates CD4 T cell cytokine production in the lung during viral disease. J Immunol. 2012; 188(4):1647-55. PMC: 3276844. DOI: 10.4049/jimmunol.1103001. View

16.

Kawai T, Akira S . TLR signaling. Semin Immunol. 2007; 19(1):24-32. DOI: 10.1016/j.smim.2006.12.004. View

17.

Collins P, Mottet G . Post-translational processing and oligomerization of the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol. 1991; 72 ( Pt 12):3095-101. DOI: 10.1099/0022-1317-72-12-3095. View

18.

Glenn G, Smith G, Fries L, Raghunandan R, Lu H, Zhou B . Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2012; 31(3):524-32. DOI: 10.1016/j.vaccine.2012.11.009. View

19.

Kapikian A, Mitchell R, Chanock R, Shvedoff R, Stewart C . An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969; 89(4):405-21. DOI: 10.1093/oxfordjournals.aje.a120954. View

20.

Chang J . Current progress on development of respiratory syncytial virus vaccine. BMB Rep. 2011; 44(4):232-7. DOI: 10.5483/BMBRep.2011.44.4.232. View